Metraipolis › archive › dc_f4ab417dbc8d

Intratumoral delivery of PD-1/PD-L1 and CTLA-4 inhibitors for recurrent/refractory solid tumors: a proof-of-concept treatment strategy — Europe PMC PMID:41459523

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41459523
DOI: 10.3389/fimmu.2025.1669924
License (as archived): solo-consultazione
Archived: 2026-11-07T16:52:58.460Z
SHA-256 of the archived text: 80957bd84cbdc1cf5d6e18683ddf2ae020f9ae7c25a471a80fb2cba251264dbd
Stable URL of this page: https://metraipolis.com/documento/dc_f4ab417dbc8d

How to cite

Intratumoral delivery of PD-1/PD-L1 and CTLA-4 inhibitors for recurrent/refractory solid tumors: a proof-of-concept treatment strategy — Europe PMC PMID:41459523 — Europe PMC (en), https://europepmc.org/article/MED/41459523 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f4ab417dbc8d (Metraipolis archive dc_f4ab417dbc8d, sha256 80957bd84cbdc1cf5d6e18683ddf2ae020f9ae7c25a471a80fb2cba251264dbd)

BibTeX

@misc{dcf4ab417dbc8d,
  title = {Intratumoral delivery of PD-1/PD-L1 and CTLA-4 inhibitors for recurrent/refractory solid tumors: a proof-of-concept treatment strategy — Europe PMC PMID:41459523},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41459523},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f4ab417dbc8d; sha256 80957bd84cbdc1cf5d6e18683ddf2ae020f9ae7c25a471a80fb2cba251264dbd},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41459523. Agents can read the archived copy with the MCP tool read_document.